Prana launches Phase II study of Alzheimer's drug

03/6/2012 | ProactiveInvestors.co.au (Australia)

Prana Biotechnology has started with the first patient in a 12-month Phase II trial that will monitor levels of amyloid in the brain and assess cognitive and functional abilities in participants treated with PBT2, the company's investigational drug for Alzheimer's disease. Study participants will undergo PiB-PET imaging prior to treatment to determine starting amyloid levels.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY